In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. But while immunotherapy drugs offer new treatment possibilities, only about 20% to 40% of patients respond ...
Apr 11, 2024
0
1
Multiple myeloma is still an incurable hematological malignancy. One of the reasons is that myeloma cells can be heterogenous and acquire resistance after anti-myeloma treatment. Immunotherapy is an attractive strategy to ...
Nov 17, 2023
0
1
University of Southampton scientists have made a breakthrough in understanding why some cancers don't respond to immunotherapy treatment, bringing fresh hope that many more people could survive the disease.
Nov 10, 2022
0
39
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors. The ...
Nov 24, 2021
0
1360
Johns Hopkins Medicine researchers have added to evidence that a gene responsible for turning off a cell's natural "suicide" signals may also be the culprit in making breast cancer and melanoma cells resistant to therapies ...
Sep 1, 2020
0
120
Prostate cancer, the second leading cause of cancer-related death for men in the United States, is poorly responsive to immunotherapy. Recent clinical trials have hinted that combining immunotherapy and radiation therapy ...
Aug 26, 2019
0
2
Unleashing the immune system to fight tumors—an approach enabled by immunotherapy—has led to remarkable outcomes in some cancer patients, but in many more, cancer cells evade the treatment and continue to spread. Now, ...
Nov 2, 2018
0
64
A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical ...
Jun 13, 2012
0
0
